Anthony Gringeri, ImmunoCellular’s senior vice president, Strategic Resources, said, “We chose to partner with Cryoport for the registrational trial of ICT-107 because of their cold chain logistics expertise and proven ability to manage the challenges of transporting valuable, temperature-sensitive cryogenically frozen materials. Of additional significance is their specialized logistics operating platform for the timely and secure delivery of our immunotherapy to the large number of patients participating in our trial in the U.S., Canada and Europe.”
ICT-107 immunotherapy targets six different antigens associated with glioblastoma, an aggressive brain cancer. More than 400 patients will be enrolled across 120 sites. The regimen in the trial is standard of care plus or minus ICT-107 immunotherapy and includes induction immunotherapy (4 doses in month 1) and maintenance (monthly doses through month 12 or progression).
Jerrell Shelton, chief executive officer of Cryoport, Inc. said, “Our agreement with ImmunoCellular Therapeutics marks a substantial milestone in Cryoport’s history as it is one of the largest volume trials we have supported. We are delighted that our advanced cryogenic logistics solutions will play an integral role in the execution of this Phase III trial. We will ensure the successful delivery of ImmunoCellular’s immune-based therapy to the 120 sites located in North America and Europe as we employ our technology based solutions.”